Sunday, 31 March 2019

My Investment Portfolio (End Mar 2019)



Transactions made in Mar 2019:
- Sold 2,000 units of M1 at $2.06

This month is a barren month for two reasons. I did not receive any dividends in the month of March and funds, from the divestment of Netlink Trust and M1, which I have been trying to redeploy has not been deployed yet.

Technically speaking, I was forced to sell M1. I sold submitted the papers to accept Konnectivity’s (owned by Keppel and SPH) voluntary conditional general offer when the news came out that Axiata had accepted the offer of S$2.06 per share for its entire stake of 28.6%. With that, M1 lost its free float as more investors accept the offer and it will be delisted after the close of the voluntary conditional general offer. Since this was going to happen, I may as well get my money out as soon as possible and put it to other use, rather than wait for Konnectivity to do a compulsory acquisition in April 19.

Singapore Reits and Business Trusts have soared once again, ever since US Federal Reserve announced that they would be more patient with future adjustments. The likes of Ascendas Reit, Keppel DC Reit and Mapletree Commercial Trust have formed new all-time high. The Mapletree Commercial Trust story is even more amazing. Within less than 8 years, its price has doubled. From an IPO price of $0.88, it is now at $1.90.

In the meantime, I am keeping watch on SGX as its price has went down to $7.3 after Hong Kong Stock Exchange shared its plans to launch futures contracts on the MSCI China A Index. With its dividends policy to pay out $0.075 every quarter, it presents a yield of around 4.1%.

Dividends received* in Mar 2019: $0

Total dividends received in 2019: $666.57

Average dividends per month: $55.55

Total Portfolio Market Value: $159,451.24

Notes:
Dividends are recognised after ex-dividend (xd) date.
Average dividends per month is calculated by dividing the dividends received by 12 months regardless of the month.
Portfolio excludes Singapore Savings Bonds.


No comments:

Post a comment